Clinical Trial Update: Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating trastuzumab deruxtecan (T-DXd) versus investigator's choice chemotherapy in patients with HER2-low, hormone receptor-positive metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced or Metastatic Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-02